Viemed Healthcare completes acquisition of Lehan's Medical Equipment
Acquisition Details: Viemed Healthcare has acquired Lehan's Medical Equipment for a base price of $26M, with additional contingent payments expected to total $2.2M.
Financial Impact: The acquisition is projected to enhance Viemed's revenue and EBITDA, leading to an increase in their full-year 2025 guidance when they report earnings for Q2 2024.
Trade with 70% Backtested Accuracy
Analyst Views on VMD
About VMD
About the author

- Exhibition Success: VeydooMax's participation at INTERMOT 2025 in Cologne attracted over 1,000 professionals and enthusiasts, showcasing its flagship V5 AI Smart Console System, which significantly enhanced brand visibility and demonstrated its market potential.
- Collaboration Opportunities: During the event, VeydooMax received letters of intent for cooperation from global motorcycle giants like Yamaha and Honda, indicating high recognition of its innovative safety technologies within the industry, which could drive future strategic partnerships.
- Technological Innovation: The V5 system integrates advanced AI-powered driver assistance features such as Blind Spot Detection and Forward Collision Warning, enhancing riding safety and meeting modern riders' demands for smart and secure solutions, thereby solidifying the company's market position.
- Industry Recognition: VeydooMax's innovative products received high praise from industry experts and media, with publications like Motorrad and Bike Magazine conducting detailed reviews of its unique smart protective features, further enhancing the brand's market influence.

Earnings Conference Call Announcement: Viemed Healthcare, Inc. will host its Third Quarter 2025 Earnings Conference Call on November 6, 2025, at 11:00 a.m. ET, with participation options provided for interested parties.
Company Overview: Viemed is a national leader in in-home, technology-enabled post-acute respiratory care, offering services such as non-invasive ventilators and sleep therapy, focusing on efficient home treatment through clinical practitioners.
Q2 2025 Financial Performance: Viemed Healthcare reported a 14.7% year-over-year revenue increase to $63.1 million, slightly missing analyst expectations, while GAAP EPS rose 115.1% to $0.08 but also fell short of projections. The company raised its full-year revenue and Adjusted EBITDA guidance following the acquisition of Lehan’s Medical Equipment.
Growth and Strategic Focus: The company experienced significant growth in patient volumes across its services, particularly in ventilator and PAP therapy segments, while also expanding into new healthcare areas such as sleep therapy and women's health. Management is closely monitoring gross margin trends amid shifts in service mix and integration of recent acquisitions.
Financial Performance: Viemed Healthcare reported a 17% increase in net revenues to $59.1 million for Q1 2025, with net income rising 64% to $2.6 million and adjusted EBITDA increasing by 26% to $12.8 million compared to the same quarter last year.
Acquisition Plans: The company announced plans to acquire Lehan's Medical Equipment for $26 million, which is expected to enhance its offerings in respiratory care and women's health, although this acquisition's impact has not yet been included in the updated full-year guidance for 2025.

Acquisition Announcement: Viemed Healthcare, Inc. has announced a definitive agreement to acquire Lehan's Medical Equipment, a family-owned healthcare provider specializing in home medical equipment and women's health, for a base purchase price of $26 million.
Growth Strategy: The acquisition aims to enhance Viemed's product offerings, particularly in maternal health, while leveraging Lehan's established reputation and community engagement to drive growth in the post-acute respiratory healthcare market.

Amplify Energy Corp Update: Shares of Amplify Energy Corp rose 15.5% in pre-market trading after the company terminated its merger agreement with Juniper Capital.
Pre-Market Stock Movements: Several stocks experienced significant changes, with AGM Group Holdings rising 47% and Spruce Biosciences falling 39.1% due to a workforce reduction plan.







